New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Videos|December 10, 2020
Supplements and Featured Publications
- The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective
Full Video Abstract: Evidence for Oral Semaglutide in Type 2 Diabetes
This infographic to The American Journal of Managed Care® supplement, "The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective," describes key managed care information on the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the management of type 2 diabetes in the United States, and appraises the clinical evidence for the first oral GLP-1RA, oral semaglutide.
Click
Articles in this issue
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
5